VIANEX S.A. THE LEADING GREEK PHARMACEUTICAL COMPANY
Quality in production Care for people
2016
LOCATION OF FACILITIES
HEADQUARTERS (greater Athens area)
Land Site: 37.000 sq.m. Premises: 8.000 sq.m.
Management & Administration Marketing & Sales Distribution of Finished Goods Warehouse
LEADING THE GREEK PHARMACEUTICAL INDUSTRY “It takes effort to reach and keep a leading position. It takes vision, dedication to the company’s goals and hard work. We feel proud in the fact that, we have succeeded in keeping VIANEX at the top of the Greek Pharmaceutical Industry. Our aim is to remain a pioneering pharmaceutical firm.
Paul J. Giannacopoulos Founder & President
The successful and long-lasting partnerships with firms of international reputation, which honour us with their trust and confidence, allow us to continuously develop our know-how for product evolution according to the highest quality standards. A key factor of our success is the high caliber personnel which fulfill the company’s objectives. We are dedicated to maintain our leading position in the Greek market. A position, which is not an end in itself, but a vision of creation, progress and excellence.”
OUR PRESENT STATUS 2015 Sales: 232,5 million euro Production Volume: 98 million trade units Market Share / Greece: 4,0% Fully specialized manufacturing process in
plants
1.110 employees
Fully integrated company from development to distribution (Development, Medical, Regulatory, Production, Marketing, Promotion, Distribution) 500 marketers & salesmen Quality assurance system and FCPA Compliance Program
VIANEX HISTORY Pharmacy & Wholesaler
Importation of Pharmaceuticals
FARMAGIAN Ltd.
VIANEX S.A.
Construction of Factory A (sterile-liquid forms)
Acquisition of Factory B (dry forms)
VIANEX HISTORY Acquisition of Factory C (lyophilized forms) VIAN S.A. Affiliate company for Retail Distribution Acquisition of the HMR production and distribution facilities
Acquisition of Factory D (cephalosporins) Established ELDRUG S.A. (Research & Development)
Approved supplier of WHO
OUR ORGANIZATION
PARTNERSHIPS
(Licensing, Co-marketing, Co-promotion)
PARTNERSHIPS INTERNATIONAL
NATIONAL
(Toll Manufacturing)
QUALITY POLICY Our Vision
“Quality in Production – Care for People”
Quality is an important element of our Mission
Quality System is assured by
- ISO 9001 Certification (all sites are certified) - Inspections and Audits by the National Authorities (all site are GMP certified) - Inspections and Audits by more that 15 international, research oriented companies/partners - Self inspection
Quality System includes
- Product quality (Development, Production, Packaging) - Service quality (Storage, Marketing, Sales, Distribution)
LONG TERM COMMITMENT TO QUALITY ALL ORGANIZATION ACTIVITIES & SITES HAVE BEEN QUALITY CERTIFIED ISO 9001 for all Plants, Marketing, Sales and Distribution
GMP by Greek FDA Authorities and Pharmaceutical International Committee (PIC) ISO 13485 for Medical Devices
EFQM Business Excellence Model
LONG TERM TO QUALITY 1993
1995
“Award of Distinction marking the 10th Anniversary of Collaboration” Merck Sharp Dohme
1995
“Quality Advocate” Eli Lilly
Quality Awards
“The 1994 Business of the Year Award” American Embassy /Hellenic- American Chamber
1996
“Quality Award 1995” Athens Chamber of Commerce/Industry
LONG TERM TO QUALITY 2003
2003
1998
1st
National Quality Award Greek Ministry of Development
“Business Excellence Distinction” Greek Management Association
2004
“1st National Quality Award” Athens Chamber of Commerce/Industry
Award of Distinction marking the 20th Anniversary of collaboration Merck Sharp Dohme
2004
“ECO-Quality Award” Eco Quality Committee
LONG TERM TO QUALITY 2007
Award by the University - Pharmaceutical Technology
2014
Award for Business Excellence “Salus Index”
2011
2013
Award “True Leaders” ICAP Group
2015
Award “Diamonds of the Greek Economy 2015” for the Most Admired Enterprises
Award “Diamonds of the Greek Economy 2012” for the Most Admired Enterprises
2015
Award for Business Excellence in Exports “Active Greece 2015”
PLANT A (greater Athens area) ANNUAL PRODUCTION CAPACITY* Liquid Injectables Line A
10.000.000 ampoules
Line B
500.000 large vials
Eye Drops
2.000.000 vials
Liquid Products Line A
6.000.000 vials
Line B
7.000.000 vials
Line C
2.000.000 vials
Semi-Solid Products Creams/ Ointments
1.000.000
Packaging 8.000.000
Land Site: 12.000 sq.m. Premises: 8.000 sq.m. Operators: 133
units
Labeling 12.000.000
*one shift daily
units
PLANT B (greater Athens area) ANNUAL PRODUCTION CAPACITY* Tablets Tablets
2.000.000.000
Coating Tablets Line A/ Film coated Tablets
100.000 kg
Line B/ Film coated Tablets
10.000 kg
Capsules Hard Gelatin capsules
150.000.000
Dry Suspensions Vials
2.000.000
Packaging Blister (PVC-Alu, PEAlu, PP-Alu, ALU-ALU)
Land Site: 17.000 sq.m. Premises: 6.400 sq.m. Operators: 135
Pouch Labeling
*one shift daily
165.000.000 8.000.000 50.000.000 boxes
PLANT C (greater Athens area) ANNUAL PRODUCTION CAPACITY*
Oncology & Non-Oncology Products: Lyophilized 10.000.000 vials ( in nine freeze dryers)
Liquid Injectables Land Site: 16.000 sq.m. Premises: 5.500 sq.m. Operators: 130
10.000.000 vials
*one shift daily
PLANT D (Patras/Industrial Zone) ANNUAL PRODUCTION CAPACITY*
Dry Injectables 10.000.000 vials
Dry Suspensions 5.500.000 vials
Capsules 65.000.000
Tablets Land Site: 16.000 sq.m. Premises: 3.800 sq.m. Operators: 47
250.000.000
*one shift daily
Quality in production Care for people